Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 2, 2003, Pages 189-197

  Wasan, Kishor M ^a   Subramanian, Ramaswamy ^a   Kwong, Mona ^a   Goldberg, Ira J ^b   Wright, Thamrah ^b   Johnston, Thomas P ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; POLOXAMER; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPID METABOLISM; MALE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; EXCIPIENTS; GLYCOPROTEINS; HYPERLIPIDEMIAS; LIPASE; LIPIDS; LIPOPROTEIN LIPASE; MALE; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0141652926     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Miettinen TA. Cholesterol absorption inhibition: A strategy for cholesterol lowering therapy. Int J Clin Pract 2001; 55: 710-16.
2. Frohlich J, Lear SA. Old and new risk factors for atherosclerosis and development of treatment recommendations. Clin Exp Pharmacol Physiol 2002; 29: 838-42.
3. Kruth HS. Lipoprotein cholesterol and atherosclerosis. Curr Mol Med 2001; 1: 633-53.
4. Zjumira GM, Wout M, Pec EA, et al. Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parent Sci Tech 1992; 46: 192-200.
5. Johnston TP, Palmer WK. Mechanism of Poloxamer 407-induced hypertriglyceridemia in the rat. Biochem Pharmacol 1993; 46: 1037-42.
6. Johnston TP, Palmer WK. Effect of Poloxamer 407 on the activity of microsomal 3-hydroxy-3 methylglutaryl CoA reductase in rats. J Cardiovasc Pharmacol 1997; 29: 580-85.
7. Palmer WK, Emeson EE, Johnston TP. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 1998; 136: 115-23.
8. Johnston TP, Baker JC, Jamal AS, et al. Potential down-regulation of HMG-CoA reductase after prolonged administration of P-407 in C57B/6 mice. J Cardiovasc Pharmacol 1999; 34: 831-42.
9. Johnston TP, Baker JC, Hall DD et al. Regression of Poloxamer-407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis 2000; 149: 303-13.
10. Johnston TP, Nguyen LB, Chu WA, et al. Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int J Pharm 2001; 229: 75-86.
11. Blonder JM, Baird L, Fulfs JC et al. Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel. Life Sci 1999; 65: 261-66.
12. Johnston TP, Miller SC. Toxicological evaluation of poloxamers for intramuscular use. J Parent Sci Technol 1985; 39: 83-8.
13. Pec EA, Wout Z, Johnston TP. Biological activity of urease formulated in poloxamer 407 following intraperitoneal injection in the rat. J Pharm Sci 1992; 81: 626-30.
14. Johnston TP, Punjabi MA, Froehlich CF. Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res 1992; 9: 421-30.
15. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 2002; 161: 245-54.
16. Jonas A. Regulation of lecithin cholesterol acyl transferase activity. Progress Lipid Res. 1998; 37: 209-34.
17. Glomset JA. The plasma lecithins:cholesterol acyl transferase reaction. J Lipid Res 1968; 9: 155-67.
18. Hoeg JM, Santamarina-Fojo S, Berard AM, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci, USA 1996; 93: 1148-53.
19. Wilson PW, Abbott RD, Castelli WP. High-density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8:737-41.
20. Assmann G, Schultze H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124(S): 11-20.
21. Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Eng J Med 1989; 321: 1311-6.
22. Drayna D, Jarnagin AS, McLean J. et al. Cloning and sequencing of human cholesteryl ester transfer protein cDNA. Nature 1987; 327: 632-4.
23. Hesler CB, Tall AR, Swenson TL, et al. Monoclonal antibodies to the Mr 74,000 cholesteryl ester transfer protein neutralize all of the cholesteryl ester and triglyceride transfer activities in human plasma. J Biol Chem 1988; 263: 5020-
24. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 34: 1255-74.
25. Ha YC, Barter PJ. Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol 1982;71: 265-9.
26. Barter P. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2029-31.
27. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutations in the cholesteryl transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97: 2917-23.
28. Marotti KR, Castle CK, Boyle TP, et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364: 73-5.
29. Rittershaus C, Miller DP, Thomas LJ, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2106-12.
30. Jiang X, Moulin P, Quinet E, et al. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. J Biol Chem 1991; 266: 4631-9.
31. Oscai LB, Palmer WK. Cellular control of triacylglycerol metabolism. In: Terjung RL, ed. Exercise and Sports Sciences Reviews, Philadelphia, PA: Franklin Institute, 1983:1-23.
32. Borensztajn J. Lipoprotein lipase. In: Scanu AM, Wissler RH, Getz GS, eds. The Biochemistry of atherosclerosis. New York: Marcel Dekker, 1979:231-45.
33. Cohen J, Vega GL, Grundy SM. Hepatic lipase: new insights from genetic and metabolic studies. Curr Opin Lipidol 1999; 10: 259-68.
34. Thuren T. Hepatic lipase and HDL metabolism. Curr. Opin. Lipidol. 2000; 11: 277-84.
35. Conelly PW, Hegele RA. Hepatic lipase deficiency. Crit Rev Clin Lab Sci 1998; 35: 547-72.
36. Santamarina-Fojo S, Haudeschild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1998; 9: 211-9.
37. Rye KA, Clay MA, Barter PJ. Remodeling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 45: 227-38.
38. Lambet G, Chase MB, Dugi K, Bensadoun A, Brewer HB Jr., Santamarina-Fojo S. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptors B1. J Lipid Res 1999; 40: 1294-1303.
39. Collet X, Tall AR, Serajuddin H, Guendouzi K, Royer L, Oliveira H, Barbaras R, Jiang XC, Francone OL. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-1. J Lipid Res 1999; 40: 1185-93.
40. Garcia A, Barbaras R, Collet X, Bogyo A, Chap H, Perret B. High-density lipoprotein 3 receptor-dependent endocytosis pathway in a human hepatoma cell line (HepG2). Biochemistry 1996; 35: 13064-71.
41. Dugi KA, Brandauer K, Schmidt N, Ramacher D, Kreuzer J. Low hepatic lipase activity is a risk factor for coronary artery disease. Atherosclerosis 2000; 151: 126 (Abstract).
42. Medzour H, Jones R, Dengremont C, Castro G, Maeda N. Hepatic lipase deficiency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E deficient mice. J Biol Chem 1997; 272: 13570-75.
43. Busch SJ, Barnhart RL, Martin GA, Fitzgerald MC, Yates MT, Mao SJ, Thomas CE, Jackson RL. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem 1994; 269: 13376-82.
44. Jansen H, Verhoeven AJM, Sijbrands EJG. Hepatic lipase: A pro- or anti-atherogenic protein? J. Lipid Res. (in press)
45. Schmolka IR. Poloxamers in the pharmaceutical industry. In: Tarch PJ, ed. Polymers for controlled drug delivery. Boca Raton: CRC Press, 1991:189-215.
46. Dobiasova M, Frohlich JJ. Assays of lecithin cholesterol acyl transferase. Methods Mol Biol, 1998; 110: 217-30.
47. Ramaswamy, M., Zhang X, Burt HM, et al. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J Pharm Sci, 1997; 86: p. 460-4.
48. Havel RJ, E.H., and Bragdon JH, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: p. 1345-1353.
49. Morton R. E and D.B. Zilversmit, Inter-relationship of lipds transferred by the lipid transfer protein isolated from human lipoprotein-deficient plasma. J Biol Chem 1983; 258: 11751-7.
50. Morton R. E and D.B. Zilversmit, Purification and characterization of lipid transfer protein(s) from human lipoprotein-deficient plasma. J Lipid Res 1982; 23: 1058-67.
51. Hocquette JF, Graulet B, Olivecrona T. Lipoprotein lipase activity and mRNA levels in bovine tissues. Comp Biochem Physiol B. Biochem Mol Biol 1998; 121: 201-12.
52. Berard AM, Clerc M, Brewer Jr. B, Santamarina-Fojo S. A normal rate of cellular cholesterol removal can be mediated by plasma from a patient with familial lecithin-cholesterol acyltransferase (LCAT) deficiency. Clin Chimica Acta 2001; 314: 131-39.
53. Oschry Y, Eisenberg S. Rat plasma lipoprotein: re-evaluation of a lipoprotein system in an animal devoid of cholesteryl ester transfer activity. J Lipid Res 1982; 23: 1099-1106.
54. Barter PJ, Lally JI. The activity of an esterified cholesterol transferring factor in human and rat serum. Biochem Biophys Acta 1978; 531: 233-36.
55. Jolley CD, Woollett LA, Turley SD, Dietschy JM. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. J Lipid Res 1998; 39: 2143-49.
56. Dietschy JM, Turley SD. Control of cholesterol turnover in the mouse. J Biol Chem 2002; 277: 3804-9.
57. Osono Y, Woollett LA, Marotti KR et al. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Proc Natl Acad Sci USA 1996; 93: 4114-9.